Rosmarinic acid (Synonyms: Labiatenic acid)

Name: Rosmarinic acid
Brand: MedChemExpress
SKU: HY-N0529
Rating: 5.0 (12 reviews)

Cat. No.: HY-N0529 Purity: 99.70%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits MAO-A, MAO-B and COMT enzymes with IC₅₀s of 50.1, 184.6 and 26.7 μM, respectively.

For research use only. We do not sell to patients.

Rosmarinic acid Chemical Structure

CAS No. : 20283-92-5

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 73	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 73	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 108	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 12 publication(s) in Google Scholar

Other Forms of Rosmarinic acid:

Rosmarinic acid racemate Get quote
Rosmarinic acid (Standard) Get quote

12 Publications Citing Use of MCE Rosmarinic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Monoamine Oxidase Isoform Specific Products:

View All Isoforms

MAO-A MAO-B

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits MAO-A, MAO-B and COMT enzymes with IC₅₀s of 50.1, 184.6 and 26.7 μM, respectively.

IC₅₀ & Target

IC50: 50.1 μM (MAO-A), 184.6 μM (MAO-B), 26.7 μM (COMT)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	0.96 μM Compound: 5	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
HeLa	IC₅₀	16.2 μM Compound: 4	Inhibition of transcription factor AP-1 binding to oligonucleotide containing TPA-responsive element in TPA-activated human HeLa cells after 1 hr by ELISA Inhibition of transcription factor AP-1 binding to oligonucleotide containing TPA-responsive element in TPA-activated human HeLa cells after 1 hr by ELISA	[PMID: 24491635]
HT-22	EC₅₀	86 μM Compound: 23	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
MOLM-13	IC₅₀	2.9 μM Compound: 19	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	7.1 μM Compound: 19	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MT4	EC₅₀	> 55 μM Compound: rosmarinic acid, 1	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay	[PMID: 18351727]
MT4	CC₅₀	55 μM Compound: rosmarinic acid, 1	Cytotoxicity against human MT4 cells by MTT method Cytotoxicity against human MT4 cells by MTT method	[PMID: 18351727]
MV4-11	IC₅₀	> 10 μM Compound: 19	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]
PC-12	EC₅₀	57.2 μM Compound: rosmarinic acid	Inhibition of amyloid beta (1 to 42 residues) (unknown origin) aggregate-induced toxicity in rat PC12 cells assessed as cell viability at 4 to 100 ug/ml pre-incubated for 24 hrs with Abeta ( 1 to 42) followed by compound-Abeta (1 to 42) mixture addition t Inhibition of amyloid beta (1 to 42 residues) (unknown origin) aggregate-induced toxicity in rat PC12 cells assessed as cell viability at 4 to 100 ug/ml pre-incubated for 24 hrs with Abeta ( 1 to 42) followed by compound-Abeta (1 to 42) mixture addition t	[PMID: 26517152]
PC-12	EC₅₀	68.1 μM Compound: rosmarinic acid	Inhibition of amyloid beta (25 to 35 residues) (unknown origin) aggregate-induced toxicity in rat PC12 cells preincubated for 1 hr followed by amyloid beta challenge measured after 24 hrs by MTT assay Inhibition of amyloid beta (25 to 35 residues) (unknown origin) aggregate-induced toxicity in rat PC12 cells preincubated for 1 hr followed by amyloid beta challenge measured after 24 hrs by MTT assay	[PMID: 26517152]
PC-3	IC₅₀	> 10 μM Compound: 5	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
RAW264.7	IC₅₀	34.2 μM Compound: 25	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
Sf9	IC₅₀	1.3 μM Compound: Rosmarinic acid	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	17 μM Compound: Rosmarinic acid	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	3.6 μM Compound: Rosmarinic acid	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	36 μM Compound: Rosmarinic acid	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	63 μM Compound: Rosmarinic acid	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	74 μM Compound: Rosmarinic acid	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
SH-SY5Y	IC₅₀	> 10 μM Compound: 5	Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]

In Vitro

Rosmarinic acid (RA) shows an in vitro multifunctional profile characterized by antioxidant effects, and monoamine oxidases (MAO-A and MAO-B) and catechol-O-methyl transferase (COMT) inhibition. Rosmarinic acid shows antioxidant effects against hydroxyl (HO(?)) and nitric oxide (NO) radicals (IC₅₀ of 29.4 and 140 μM, respectively), and inhibition of lipid peroxidation (IC₅₀ of 19.6 μM)^[1]. Rosmarinic acid (RA) exerts a significant cytoprotective effect by scavenging intracellular ROS induced by UVB. In H₂O₂-treated cells, 2.5 μM Rosmarinic acid scavenges 60% of intracellular ROS compared to 77% of intracellular ROS scavenging effect in N-acetyl-L-cysteine (NAC)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rosmarinic acid (RA) is a widespread phenolic ester compound in the plants, particularly those in the Labiatae family of herbs, such as Rosmarinus officinali, Salvia miltiorrhiza, and Prunella vulgaris. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. In the DSS-induced colitis model, Treatment with Rosmarinic acid (30, 60?mg/kg, p.o.) markedly attenuates the production of cytokines^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

360.31

Formula

C₁₈H₁₆O₈

CAS No.

20283-92-5

Appearance

Solid

Color

Light yellow to light brown

SMILES

OC([C@H](OC(/C=C/C1=CC(O)=C(O)C=C1)=O)CC2=CC(O)=C(O)C=C2)=O

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (173.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7754 mL	13.8769 mL	27.7539 mL
5 mM	0.5551 mL	2.7754 mL	5.5508 mL
10 mM	0.2775 mL	1.3877 mL	2.7754 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.70%

Select Batch:

Data Sheet (278 KB) SDS (392 KB)

COA (247 KB) HNMR (119 KB) RP-HPLC (206 KB)

Handling Instructions (2659 KB)

References

[1]. Andrade JM, et al. Combining in vitro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45. [Content Brief]

[2]. Fernando PM, et al. Rosmarinic Acid Attenuates Cell Damage against UVB Radiation-Induced Oxidative Stress via Enhancing Antioxidant Effects in Human HaCaT Cells. Biomol Ther (Seoul). 2016 Jan;24(1):75-84. [Content Brief]

[3]. Jin BR, et al. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. Sci Rep. 2017 Apr 6;7:46252. [Content Brief]

Cell Assay ^[2]	Human keratinocytes (HaCaT cells) are treated with Rosmarinic acid (0.625, 1.25, 2.5, or 5 μM) and exposed to UVB radiation 1 h later. They are then incubated at 37°C for 48 h. At this time, MTT is added to each well to obtain a total reaction volume of 200 μL. After 4 h incubation, the supernatant is removed by aspiration. The formazan crystals in each well are dissolved in dimethyl sulfoxide (DMSO; 150 μL), and the absorbance at 540 nm is measured on a scanning multi-well spectrophotometer^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] Experimental colitis is induced by giving mice drinking water ad libitum containing 5% (w/v) DSS for 7 days. Mice of each of the groups are monitored carefully every day to confirm that they have consumed an approximately equal volume of water containing DSS. For each experiment, the mice are divided into five experimental groups (n = 10/group). The first group is kept as the vehicle-treated control, and the second group is given drinking water with DSS only during the experimental period. The other three groups consist of mice receiving 5% DSS who are administrated 5-ASA (75 mg/kg/day p.o.) or Rosmarinic acid (30 or 60 mg/kg/day p.o.) daily for 7 days. Control groups are given the vehicle daily for 7 days as appropriate. Administration of each drug is initiated simultaneously with the DSS treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Andrade JM, et al. Combining in vitro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45. [Content Brief] [2]. Fernando PM, et al. Rosmarinic Acid Attenuates Cell Damage against UVB Radiation-Induced Oxidative Stress via Enhancing Antioxidant Effects in Human HaCaT Cells. Biomol Ther (Seoul). 2016 Jan;24(1):75-84. [Content Brief] [3]. Jin BR, et al. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. Sci Rep. 2017 Apr 6;7:46252. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7754 mL	13.8769 mL	27.7539 mL	69.3847 mL
	5 mM	0.5551 mL	2.7754 mL	5.5508 mL	13.8769 mL
	10 mM	0.2775 mL	1.3877 mL	2.7754 mL	6.9385 mL
	15 mM	0.1850 mL	0.9251 mL	1.8503 mL	4.6256 mL
	20 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4692 mL
	25 mM	0.1110 mL	0.5551 mL	1.1102 mL	2.7754 mL
	30 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	40 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	50 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL
	60 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL
	80 mM	0.0347 mL	0.1735 mL	0.3469 mL	0.8673 mL
	100 mM	0.0278 mL	0.1388 mL	0.2775 mL	0.6938 mL

Rosmarinic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rosmarinic acid20283-92-5Labiatenic acidMonoamine OxidaseCOMTApoptosisEndogenous MetaboliteMAOCatechol-O-methyltransferaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Rosmarinic acid (Synonyms: Labiatenic acid)

Customer Review

Other Forms of Rosmarinic acid:

Rosmarinic acid Related Antibodies

12 Publications Citing Use of MCE Rosmarinic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Monoamine Oxidase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Rosmarinic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Rosmarinic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report